Prescribers’ satisfaction with delivering medications for opioid use disorder

Autor:	Eric Haram, Todd Molfenter, Hanna Kim, Nora Jacobson, Julie Horst, Hannah K. Knudsen, Randy Brown, Lynn M. Madden, Jee-Seon Kim
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	medicine.medical_specialty media_common.quotation_subject Narcotic Antagonists Personal Satisfaction Disease cluster Naltrexone law.invention extended-release naltrexone Randomized controlled trial Social pathology. Social and public welfare. Criminology law Medicine Humans prescriber satisfaction HV1-9960 media_common business.industry Health Policy Public health Research Opioid use disorder opioid use disorder medicine.disease Opioid-Related Disorders buprenorphine Analgesics Opioid Psychiatry and Mental health Health psychology Feeling Family medicine Public aspects of medicine RA1-1270 business medicine.drug Buprenorphine
Zdroj:	Substance Abuse Treatment, Prevention, and Policy, Vol 16, Iss 1, Pp 1-8 (2021) Substance Abuse Treatment, Prevention, and Policy
ISSN:	0292-6482
Popis:	Background Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering these two types of MOUD. The current study describes the satisfaction of prescribers delivering buprenorphine and XR-naltrexone while examining whether satisfaction is associated with current patient census and organizational environment. Methods As part of a cluster randomized clinical trial (RCT) focused on expanding access to medication for opioid use disorder, 41 MOUD prescribers in Florida, Ohio, and Wisconsin completed a web-based survey. The survey included measures of prescriber satisfaction with delivering buprenorphine treatment and XR-naltrexone. In addition, the survey measured several prescriber characteristics and their perceptions of the organizational environment. Results Prescribers were generally satisfied with their work in delivering these two types of MOUD. Prescribers reporting a greater number of patients (r = .46, p = .006), those who would recommend the center to others (r = .56, p < .001), and those reporting positive relationships with staff (r = .56, p < .001) reported significantly greater overall satisfaction with delivering buprenorphine treatment. Prescribers who more strongly endorsed feeling overburdened reported lower overall buprenorphine satisfaction (r = -.37, p = .02). None of the prescriber characteristics or perceptions of the organizational environment were significantly associated with overall satisfaction with delivering XR-naltrexone treatment. Conclusions The generally high levels of satisfaction with both types of MOUD is notable given that prescriber dissatisfaction can lead to turnover and impact intentions to leave the profession. Future research should continue to explore the prescriber characteristics and organizational factors associated with satisfaction in providing different types of MOUD. Registration ClinicalTrials.gov. NCT02926482. Date of registration: September 9, 2016. https://clinicaltrials.gov/ct2/show/NCT02926482.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c445d5fedd5488653f380fd131824c4 https://doaj.org/article/d0e32107a12a4a998024a37ca54c8114 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.